Gossamer Bio Under Siege: Investor Lawsuits and Surging Costs Test Resilience

The biotech group Gossamer Bio finds itself caught between a failed clinical trial, a deepening financial hole, and a mounting legal threat. With a critical FDA meeting just weeks away, the company must navigate not only regulatory scrutiny but also disgruntled shareholders and a stretched balance sheet.

First-quarter results released in mid-May laid bare the financial strain. Gossamer Bio posted a net loss of $46.7 million, or $0.20 per share, widening from $36.6 million in the same period last year. That figure came in well below analyst expectations, which had pegged the per-share loss at $0.17. Revenue, however, jumped to $17.0 million, almost entirely from the collaboration with the Chiesi Group. The top-line improvement was not enough to offset the accelerating cash burn, with research and development costs rising to $43.1 million from $38.0 million — a direct consequence of the ongoing clinical work on the lead asset Seralutinib. General and administrative expenses also swelled, reaching $18.7 million, partly due to one-time charges tied to a workforce reduction.

The cash position is now a central concern. Gossamer Bio ended the first quarter with $99.2 million in cash, cash equivalents, and marketable securities. Management believes that sum will fund operations into the first quarter of 2027. To further ease the pressure, the company is pushing through an exchange offer for its 5.00% convertible senior notes due 2027, aiming to retire roughly $128 million in debt and extend the maturity profile to 2030.

Should investors sell immediately? Or is it worth buying Gossamer Bio?

The urgency behind that debt reshuffling is amplified by the fallout from the Phase 3 PROSERA study. In February, Seralutinib narrowly missed its primary endpoint of improving walking distance in patients with pulmonary arterial hypertension. Shares collapsed 80% on the day of the data release, falling from above $2 to just pennies. Year-to-date, the stock has shed more than 93% of its value, leaving the company with a market capitalisation of approximately $51 million.

The study's failure has also sparked a class action lawsuit. Several US law firms are gathering shareholders, alleging that Gossamer Bio misrepresented the patient composition of the trial. According to the complaint, more than half of the participants were already receiving other therapies, which skewed the statistical analysis. The lead plaintiff deadline falls in early June, and if the allegations hold, the company could face substantial penalties. Daily trading volumes have surged as a result, with millions of shares changing hands amid extreme volatility.

On the clinical front, a pivotal moment arrives in June 2026, when the FDA has scheduled a face-to-face pre-NDA Type B meeting. The discussions will centre on the PROSERA data and the potential path toward a New Drug Application. Gossamer Bio is still targeting a submission in September, but the timeline now hinges on the outcome of those talks. Barclays, for its part, is not optimistic. The bank reiterated its "Underweight" rating on Tuesday, May 19, while slashing the price target from $0.30 to $0.28, citing the wider-than-expected losses and the legal overhang.

Between the courtroom, the laboratory, and the balance sheet, Gossamer Bio is being pulled in three directions at once. The next few months will show whether it can hold its course long enough to reach the FDA finish line.

Ad

Gossamer Bio Stock: New Analysis - 21 May

Fresh Gossamer Bio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gossamer Bio analysis...

en | US38341P1021 | GOSSAMER | boerse | 69385967 |